These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26749582)

  • 1. Aspirin use is associated with lower indices of liver fibrosis among adults in the United States.
    Jiang ZG; Feldbrügge L; Tapper EB; Popov Y; Ghaziani T; Afdhal N; Robson SC; Mukamal KJ
    Aliment Pharmacol Ther; 2016 Mar; 43(6):734-43. PubMed ID: 26749582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-fasting triglyceride levels are associated with non-invasive markers of advanced liver fibrosis among adults in the United States.
    Jiang ZG; Tsugawa Y; Tapper EB; Lai M; Afdhal N; Robson SC; Mukamal KJ
    Aliment Pharmacol Ther; 2015 Jul; 42(1):106-16. PubMed ID: 25913437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey.
    Shen H; Shahzad G; Jawairia M; Bostick RM; Mustacchia P
    Aliment Pharmacol Ther; 2014 Nov; 40(9):1066-73. PubMed ID: 25176122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA.
    Wijarnpreecha K; Thongprayoon C; Scribani M; Ungprasert P; Cheungpasitporn W
    Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):404-410. PubMed ID: 29215435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
    Polyzos SA; Goulis DG; Kountouras J; Mintziori G; Chatzis P; Papadakis E; Katsikis I; Panidis D
    Hormones (Athens); 2014; 13(4):519-31. PubMed ID: 25402369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease.
    Li Q; Lu C; Li W; Huang Y; Chen L
    Oncotarget; 2017 Apr; 8(17):28641-28649. PubMed ID: 28415736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011).
    Lee YH; Kim SU; Song K; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Han KH
    Hepatology; 2016 Mar; 63(3):776-86. PubMed ID: 26638128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.
    Polyzos SA; Kountouras J; Mantzoros CS; Polymerou V; Katsinelos P
    Diabetes Obes Metab; 2017 Dec; 19(12):1805-1809. PubMed ID: 28452101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
    Goldberg D; Ditah IC; Saeian K; Lalehzari M; Aronsohn A; Gorospe EC; Charlton M
    Gastroenterology; 2017 Apr; 152(5):1090-1099.e1. PubMed ID: 28088461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
    Mansoor S; Yerian L; Kohli R; Xanthakos S; Angulo P; Ling S; Lopez R; Christine CK; Feldstein AE; Alkhouri N
    Dig Dis Sci; 2015 May; 60(5):1440-7. PubMed ID: 25540086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between low-dose aspirin and periodontal disease: results from the continuous national health and nutrition examination survey (NHANES) 2011-2012.
    Kotsakis GA; Thai A; Ioannou AL; Demmer RT; Michalowicz BS
    J Clin Periodontol; 2015 Apr; 42(4):333-41. PubMed ID: 25683058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.
    Tana C; Tana M; Rossi S; Silingardi M; Schiavone C
    J Ultrasound; 2016 Sep; 19(3):183-9. PubMed ID: 27635163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non invasive assessment of liver fibrosis in chronic hemodialysis patients with viral hepatitis C.
    Arrayhani M; Sqalli T; Tazi N; El Youbi R; Chaouch S; Aqodad N; Ibrahimi SA
    Pan Afr Med J; 2015; 22():273. PubMed ID: 26958136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice.
    Yoshida S; Ikenaga N; Liu SB; Peng ZW; Chung J; Sverdlov DY; Miyamoto M; Kim YO; Ogawa S; Arch RH; Schuppan D; Popov Y
    Gastroenterology; 2014 Dec; 147(6):1378-92. PubMed ID: 25173753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH.
    Kruger FC; Daniels CR; Kidd M; Swart G; Brundyn K; van Rensburg C; Kotze M
    S Afr Med J; 2011 Jun; 101(7):477-80. PubMed ID: 21920102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver fibrosis: noninvasive assessment using supersonic shear imaging and FIB4 index in patients with non-alcoholic fatty liver disease.
    Takeuchi H; Sugimoto K; Oshiro H; Iwatsuka K; Kono S; Yoshimasu Y; Kasai Y; Furuichi Y; Sakamaki K; Itoi T
    J Med Ultrason (2001); 2018 Apr; 45(2):243-249. PubMed ID: 29128938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic value of non-invasive tests for the evaluation of liver fibrosis in chronic hepatitis B patients.
    Erdogan S; Dogan HO; Sezer S; Uysal S; Ozhamam E; Kayacetin S; Koca Y
    Scand J Clin Lab Invest; 2013; 73(4):300-8. PubMed ID: 23514016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH.
    Vilar-Gomez E; Calzadilla-Bertot L; Friedman SL; Gra-Oramas B; Gonzalez-Fabian L; Lazo-Del Vallin S; Diago M; Adams LA
    Liver Int; 2017 Dec; 37(12):1887-1896. PubMed ID: 28544769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease.
    Peleg N; Issachar A; Sneh-Arbib O; Shlomai A
    Dig Liver Dis; 2017 Oct; 49(10):1133-1138. PubMed ID: 28572039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of anti-platelet agents in the prevention of hepatic fibrosis in patients at risk for chronic liver disease: a systematic review and meta-analysis.
    Iqbal U; Dennis BB; Li AA; Cholankeril G; Kim D; Khan MA; Ahmed A
    Hepatol Int; 2019 Jan; 13(1):84-90. PubMed ID: 30539518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.